ClinicalTrials.Veeva

Menu
C

Cancer and Hematology Centers Of Western Michigan | CHCWM East - Grand Rapids, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Nivolumab
Cyclophosphamide
Vincristine
Doxorubicin
Atezolizumab
Irinotecan
Prednisone
LY3537982
Durvalumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 34 total trials
Locations recently updated

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\...

Enrolling
Melanoma
Biological: Pembrolizumab
Biological: V940

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Enrolling
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Drug: Physician's Choice medications
Drug: Pacritinib

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Carboplatin
Drug: LY3537982

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abirater...

Enrolling
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostatic Neoplasms
Drug: Enzalutamide
Drug: Dexamethasone

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...

Active, not recruiting
Metastatic Adenocarcinoma of the Pancreas
Drug: Leucovorin
Drug: Gemcitabine

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Enrolling
Diffuse Large B-cell Lymphoma (DLBCL)
Drug: Doxorubicin
Drug: Prednisone/Prednisolone

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously u...

Enrolling
Follicular Lymphoma (FL)
Drug: Odronextamab
Drug: Vincristine

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Drug: 5-FU
Biological: Lenvatinib

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to ful...

Enrolling
Metastatic Breast Cancer
Drug: Lasofoxifene in combination with abemaciclib
Drug: Fulvestrant in combination with abemaciclib

This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics...

Active, not recruiting
Extensive-stage Small-cell Lung Cancer
Drug: Ifinatamab Deruxtecan (I-DXd)

This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy fo...

Active, not recruiting
Small Cell Lung Carcinoma
Drug: Saline placebo
Biological: Atezolizumab

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of...

Active, not recruiting
Biliary Tract Cancer
Drug: Leucovorin
Drug: Nanoliposomal-Irinotecan
Locations recently updated

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...

Enrolling
Small-Cell Lung Cancer
Extensive-Stage Small-Cell Lung Cancer
Drug: Tarlatamab
Drug: Durvalumab

The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination wit...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Biological: Pembrolizumab
Drug: Cisplatin

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess pr...

Active, not recruiting
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Relapsed/Refractory Multiple Myeloma (RRMM)
Drug: ASTX727
Drug: Dexamethasone

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Gemcitabine
Drug: Pemetrexed

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Celgene logo
Pfizer logo
Regeneron Pharmaceuticals logo
A
Amgen logo
Bristol-Myers Squibb (BMS) logo
CTI BioPharma logo
Daiichi Sankyo logo
Gilead Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems